Novartis unveils breakthroughs in iron catalysis and p38α inhibitors
NVSNVDA
Statements (3)
- Bullish
Novartis reported a breakthrough in the discovery of potent and selective MAO-B inhibitors from a morpholine-substituted chalcone library, with TC12 identified as the strongest inhibitor.
- Bullish
Novartis reported a first-in-class p38α-isoform selective inhibitor with 12,000-fold selectivity improvement over currently available compounds.
- Bullish
Novartis reported a breakthrough in nonheme iron catalysis for indole oxidation, enabling efficient synthesis of natural products and pharmaceuticals.